Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events

Sean P. Collins, Kimberly W. Hart, Christopher J. Lindsell, Gregory J. Fermann, Neal L. Weintraub, Karen F. Miller, Susan N. Roll, Matthew I. Sperling, Douglas B. Sawyer, Alan B. Storrow

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Aims Reliable detectors of worsening renal function (WRF) in Emergency Department (ED) patients with acute heart failure (AHF) are limited. We hypothesized that initial urinary neutrophil gelatinase-associated lipocalcin (NGAL) levels, and changes in urinary NGAL levels after initial ED AHF therapy, would be associated with WRF and adverse events. Methods and resultsUrinary NGAL upon ED presentation and 1224 h after ED treatment was measured in a cohort of ED patients with AHF. NGAL was corrected for urinary creatinine (uCr). WRF was defined as RIFLE stages 1, 2, or 3, or a creatinine increase of <0.3 mg/dL. Patients were prospectively followed for 5-and 30-day adverse cardiovascular events. The 399 patients had a median age of 63 years, 50 were Caucasian, and 62 were male. Those with WRF at 7296 h were more likely to have a higher initial NGAL value (71 vs. 32 ng NGAL/mg uCr) (P 0.005), and a higher NGAL level at 1224 h after ED therapy (107 vs. 25ng NGAL/mg uCr, P < 0.001). In a multivariable model, NGAL at 1224 h remained a significant predictor of WRF (P 0.012). Of all variables available 1224 h after initial therapy, the only significant predictor of 30-day events was an elevated urinary NGAL level (P 0.02). ConclusionsUrinary NGAL levels determined 1224 h after ED therapy are significantly associated with both WRF at 7296 h and 30-day adverse events. This suggests that early management strategies may have an impact on subsequent WRF and outcomes. If confirmed, NGAL may have a role for guiding therapeutic decisions.

Original languageEnglish (US)
Pages (from-to)1020-1029
Number of pages10
JournalEuropean Journal of Heart Failure
Volume14
Issue number9
DOIs
StatePublished - Sep 1 2012

Fingerprint

Gelatinases
Neutrophils
Heart Failure
Kidney
Hospital Emergency Service
Emergency Treatment
Creatinine
Therapeutics

Keywords

  • ED
  • Heart failure
  • NGAL
  • Outcomes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events. / Collins, Sean P.; Hart, Kimberly W.; Lindsell, Christopher J.; Fermann, Gregory J.; Weintraub, Neal L.; Miller, Karen F.; Roll, Susan N.; Sperling, Matthew I.; Sawyer, Douglas B.; Storrow, Alan B.

In: European Journal of Heart Failure, Vol. 14, No. 9, 01.09.2012, p. 1020-1029.

Research output: Contribution to journalArticle

Collins, Sean P. ; Hart, Kimberly W. ; Lindsell, Christopher J. ; Fermann, Gregory J. ; Weintraub, Neal L. ; Miller, Karen F. ; Roll, Susan N. ; Sperling, Matthew I. ; Sawyer, Douglas B. ; Storrow, Alan B. / Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events. In: European Journal of Heart Failure. 2012 ; Vol. 14, No. 9. pp. 1020-1029.
@article{fa50628087c246ad856ef0c50d453b0f,
title = "Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events",
abstract = "Aims Reliable detectors of worsening renal function (WRF) in Emergency Department (ED) patients with acute heart failure (AHF) are limited. We hypothesized that initial urinary neutrophil gelatinase-associated lipocalcin (NGAL) levels, and changes in urinary NGAL levels after initial ED AHF therapy, would be associated with WRF and adverse events. Methods and resultsUrinary NGAL upon ED presentation and 1224 h after ED treatment was measured in a cohort of ED patients with AHF. NGAL was corrected for urinary creatinine (uCr). WRF was defined as RIFLE stages 1, 2, or 3, or a creatinine increase of <0.3 mg/dL. Patients were prospectively followed for 5-and 30-day adverse cardiovascular events. The 399 patients had a median age of 63 years, 50 were Caucasian, and 62 were male. Those with WRF at 7296 h were more likely to have a higher initial NGAL value (71 vs. 32 ng NGAL/mg uCr) (P 0.005), and a higher NGAL level at 1224 h after ED therapy (107 vs. 25ng NGAL/mg uCr, P < 0.001). In a multivariable model, NGAL at 1224 h remained a significant predictor of WRF (P 0.012). Of all variables available 1224 h after initial therapy, the only significant predictor of 30-day events was an elevated urinary NGAL level (P 0.02). ConclusionsUrinary NGAL levels determined 1224 h after ED therapy are significantly associated with both WRF at 7296 h and 30-day adverse events. This suggests that early management strategies may have an impact on subsequent WRF and outcomes. If confirmed, NGAL may have a role for guiding therapeutic decisions.",
keywords = "ED, Heart failure, NGAL, Outcomes",
author = "Collins, {Sean P.} and Hart, {Kimberly W.} and Lindsell, {Christopher J.} and Fermann, {Gregory J.} and Weintraub, {Neal L.} and Miller, {Karen F.} and Roll, {Susan N.} and Sperling, {Matthew I.} and Sawyer, {Douglas B.} and Storrow, {Alan B.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1093/eurjhf/hfs087",
language = "English (US)",
volume = "14",
pages = "1020--1029",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events

AU - Collins, Sean P.

AU - Hart, Kimberly W.

AU - Lindsell, Christopher J.

AU - Fermann, Gregory J.

AU - Weintraub, Neal L.

AU - Miller, Karen F.

AU - Roll, Susan N.

AU - Sperling, Matthew I.

AU - Sawyer, Douglas B.

AU - Storrow, Alan B.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Aims Reliable detectors of worsening renal function (WRF) in Emergency Department (ED) patients with acute heart failure (AHF) are limited. We hypothesized that initial urinary neutrophil gelatinase-associated lipocalcin (NGAL) levels, and changes in urinary NGAL levels after initial ED AHF therapy, would be associated with WRF and adverse events. Methods and resultsUrinary NGAL upon ED presentation and 1224 h after ED treatment was measured in a cohort of ED patients with AHF. NGAL was corrected for urinary creatinine (uCr). WRF was defined as RIFLE stages 1, 2, or 3, or a creatinine increase of <0.3 mg/dL. Patients were prospectively followed for 5-and 30-day adverse cardiovascular events. The 399 patients had a median age of 63 years, 50 were Caucasian, and 62 were male. Those with WRF at 7296 h were more likely to have a higher initial NGAL value (71 vs. 32 ng NGAL/mg uCr) (P 0.005), and a higher NGAL level at 1224 h after ED therapy (107 vs. 25ng NGAL/mg uCr, P < 0.001). In a multivariable model, NGAL at 1224 h remained a significant predictor of WRF (P 0.012). Of all variables available 1224 h after initial therapy, the only significant predictor of 30-day events was an elevated urinary NGAL level (P 0.02). ConclusionsUrinary NGAL levels determined 1224 h after ED therapy are significantly associated with both WRF at 7296 h and 30-day adverse events. This suggests that early management strategies may have an impact on subsequent WRF and outcomes. If confirmed, NGAL may have a role for guiding therapeutic decisions.

AB - Aims Reliable detectors of worsening renal function (WRF) in Emergency Department (ED) patients with acute heart failure (AHF) are limited. We hypothesized that initial urinary neutrophil gelatinase-associated lipocalcin (NGAL) levels, and changes in urinary NGAL levels after initial ED AHF therapy, would be associated with WRF and adverse events. Methods and resultsUrinary NGAL upon ED presentation and 1224 h after ED treatment was measured in a cohort of ED patients with AHF. NGAL was corrected for urinary creatinine (uCr). WRF was defined as RIFLE stages 1, 2, or 3, or a creatinine increase of <0.3 mg/dL. Patients were prospectively followed for 5-and 30-day adverse cardiovascular events. The 399 patients had a median age of 63 years, 50 were Caucasian, and 62 were male. Those with WRF at 7296 h were more likely to have a higher initial NGAL value (71 vs. 32 ng NGAL/mg uCr) (P 0.005), and a higher NGAL level at 1224 h after ED therapy (107 vs. 25ng NGAL/mg uCr, P < 0.001). In a multivariable model, NGAL at 1224 h remained a significant predictor of WRF (P 0.012). Of all variables available 1224 h after initial therapy, the only significant predictor of 30-day events was an elevated urinary NGAL level (P 0.02). ConclusionsUrinary NGAL levels determined 1224 h after ED therapy are significantly associated with both WRF at 7296 h and 30-day adverse events. This suggests that early management strategies may have an impact on subsequent WRF and outcomes. If confirmed, NGAL may have a role for guiding therapeutic decisions.

KW - ED

KW - Heart failure

KW - NGAL

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=84865453733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865453733&partnerID=8YFLogxK

U2 - 10.1093/eurjhf/hfs087

DO - 10.1093/eurjhf/hfs087

M3 - Article

C2 - 22733980

AN - SCOPUS:84865453733

VL - 14

SP - 1020

EP - 1029

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 9

ER -